IDEXX Laboratories, Inc. (NASDAQ:IDXX) Position Raised by Mizuho Securities USA LLC

Mizuho Securities USA LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 45.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,761 shares of the company's stock after purchasing an additional 2,424 shares during the period. Mizuho Securities USA LLC's holdings in IDEXX Laboratories were worth $3,209,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in IDXX. Flossbach Von Storch SE lifted its stake in shares of IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after purchasing an additional 464,791 shares during the period. William Blair Investment Management LLC grew its stake in shares of IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after purchasing an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd purchased a new stake in IDEXX Laboratories in the 4th quarter worth about $113,104,000. Finally, Vontobel Holding Ltd. grew its holdings in shares of IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock worth $173,051,000 after purchasing an additional 198,404 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Remove Ads

IDEXX Laboratories Stock Up 1.2 %

Shares of NASDAQ:IDXX traded up $4.83 during trading hours on Thursday, reaching $422.54. The stock had a trading volume of 998,880 shares, compared to its average volume of 557,130. The firm's 50 day moving average is $437.26 and its 200-day moving average is $443.87. The stock has a market capitalization of $34.25 billion, a price-to-earnings ratio of 39.60, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Barclays increased their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.